Leader of Johnson & Johnson 3D Printing Center of Excellence Outlines Advantages of Customized Knee Implants
16 October 2017 - 11:00PM
ConforMIS, Inc. (NASDAQ:CFMS), a medical technology company that
offers joint replacement implants customized to fit each patient's
unique anatomy, today announced that, while the industry has begun
to acknowledge the value of customized knee replacement implant
systems compared to traditional off-the-shelf implant systems, it
has obtained additional positive clinical data regarding the
performance of its customized partial knee replacement implants.
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/38f395f7-6e0c-415c-b971-eafda91979ec
Recently, Sam Onukuri, head of Johnson & Johnson’s 3D
Printing Center of Excellence, acknowledged the advantages of
customized knee implants and instruments that are developed based
on a CT or MRI scan of a patient’s anatomy. In an interview
generally discussing the advantages of additive manufacturing
published in GE Reports by General Electric (GE) and in an
“Employee Spotlight” article published by Johnson & Johnson,
Onukuri noted the potential advantages of customized knee implants
that may reduce both “pain and the recuperation time” compared to
traditional off-the-shelf implant systems that come in a limited
range of sizes. “Physicians make every effort to find the
implant that fits best,” Onukuri says. “But it’s never a perfect
match, and the same is true for the tools. As a result, the surgery
takes longer — and so can healing and recovery — and the fit may
not be perfect.” On the other hand, Onukuri noted that “customized
solutions” based on patient CT or MRI scans “can achieve an exact
fit for the joint.”
While the orthopedic industry researches potential customized
alternatives to traditional off-the-shelf implant technology,
ConforMIS continues to develop a growing body of positive clinical
data regarding its existing customized knee implants. Most
recently, in a study evaluating knee strength and mechanics that
compared healthy control patients to those with either a modern
off-the-shelf total knee replacement (TKR) or a customized
bi-compartmental knee replacement (BKR), the authors concluded that
the “study shows that BKR patients exhibit better strength and
mechanics while performing activities of daily living.”
According to the study results: the TKR group walked significantly
slower when compared to both the BKR group and healthy controls (p
< 0.05); the TKR knee had less peak extensor moment at stance
than both the BKR and healthy control knees (p < 0.05); and both
the BKR and healthy control knees displayed larger internal
rotation at stance than that of the TKR knee (p < 0.05).
The results of the study, for which ConforMIS provided financial
support, were published online by International Orthopaedics on
September 4, 2017.
“We are very pleased that the industry is now beginning to
recognize the advantages and potentially transformative nature of
customized knee implant and instrumentation solutions,” said Mark
Augusti, Chief Executive Officer and President of ConforMIS.
“ConforMIS has been a champion of customized implant
technology for over a decade, and the body of clinical data
demonstrating both the clinical and the economic advantages of
customized total and partial knee implant systems continues to
grow.”
About ConforMIS, Inc.
ConforMIS is a medical technology company that uses its
proprietary iFit Image-to-Implant technology platform to develop,
manufacture and sell joint replacement implants that are
individually sized and shaped, or customized, to fit each patient’s
unique anatomy. ConforMIS offers a broad line of customized
knee implants and pre-sterilized, single-use instruments delivered
in a single package to the hospital. In recent clinical
studies, ConforMIS iTotal CR demonstrated superior clinical
outcomes, including better function and greater patient
satisfaction, compared to traditional, off-the-shelf
implants. ConforMIS owns or exclusively in-licenses
approximately 450 issued patents and pending patent applications
that cover customized implants and patient-specific instrumentation
for all major joints.
For more information, visit www.conformis.com.
Cautionary Statement Regarding Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for ConforMIS, including statements about the
transformative nature of customized implant systems, the economic
or other impacts and advantages of using customized implants, as
well as other statements containing the words “anticipate,”
“believe,” “continue,” “could,” “estimate,” “expect,” “intend,”
“may,” “might,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “will,” or “would” and similar expressions,
constitute forward-looking statements within the meaning of the
safe harbor provisions of The Private Securities Litigation Reform
Act of 1995. We may not actually achieve the plans, intentions or
expectations disclosed in our forward-looking statements, and you
should not place undue reliance on our forward-looking statements.
Actual results or events could differ materially from the plans,
intentions and expectations disclosed in the forward-looking
statements we make as a result of a variety of risks and
uncertainties, including risks related to our product development
and commercialization efforts, and the other risks and
uncertainties described in the “Risk Factors” sections of our
public filings with the Securities and Exchange Commission. In
addition, the forward-looking statements included in this press
release represent ConforMIS’s views as of the date hereof.
ConforMIS anticipates that subsequent events and developments may
cause ConforMIS’s views to change. However, while ConforMIS may
elect to update these forward-looking statements at some point in
the future, ConforMIS specifically disclaims any obligation to do
so. These forward-looking statements should not be relied upon as
representing ConforMIS’s views as of any date subsequent to the
date hereof.
The photo is also available via AP PhotoExpress.
CONTACT:
Beth Bestbeth.best@conformis.com(781) 345-9032
Investor Contact:Oksana Bradleyir@conformis.com(781)
374-5598
Conformis (NASDAQ:CFMS)
Historical Stock Chart
From Apr 2024 to May 2024
Conformis (NASDAQ:CFMS)
Historical Stock Chart
From May 2023 to May 2024